How to access Kesimpta from India, the named-patient import pathway, 2026
By Reserve Meds · Clinical and regulatory team · Last reviewed 2026-06-04
Quick orientation
An Indian patient with relapsing multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting (RRMS), and active secondary-progressive disease (SPMS), may receive a prescription for Kesimpta (ofatumumab) from their treating neurologist. Kesimpta is FDA-approved (US approval August 2020), developed by Novartis, and is a recognised subcutaneous self-injected anti-CD20 monoclonal antibody option for relapsing MS in adults. In India, Kesimpta is not routinely registered for domestic outpatient dispensing, and access is typically coordinated through the named-patient import pathway under the Central Drugs Standard Control Organisation (CDSCO) framework.
This guide explains the pathway, the documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Kesimpta is a fully human anti-CD20 monoclonal antibody that depletes B cells. Unlike infusion-based anti-CD20 therapies (Ocrevus, Briumvi, rituximab), Kesimpta is self-administered at home as a subcutaneous (SC) injection using a prefilled Sensoready pen. The standard regimen is 20 mg SC at Weeks 0, 1, and 2 (loading doses), followed by 20 mg SC once every four weeks thereafter. The at-home dosing profile is a core reason many patients and neurologists select Kesimpta: it preserves patient mobility, removes infusion-centre dependence, and reduces caregiver burden for patients in Tier 2 and Tier 3 Indian cities far from an MS-experienced infusion unit.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Eligibility requires a confirmed relapsing MS diagnosis per McDonald criteria, MRI evidence, and a clinical rationale for anti-CD20 therapy. Before first dose, your neurologist will screen for active or chronic hepatitis B (HBsAg and anti-HBc), update vaccinations (including live vaccines before B-cell depletion), assess baseline serum immunoglobulins (IgG, IgA, IgM), and screen for active infection. During therapy, immunoglobulin and infection surveillance continues at scheduled intervals.
Why Indian patients route via the named-patient pathway
Yes, Kesimpta is legally importable into India through the CDSCO personal-import / named-patient framework administered under the Drugs and Cosmetics Rules. The mechanism permits import of an unregistered medicine for a specific named patient when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable for the patient, (c) a qualified Indian physician accepts clinical responsibility, and (d) chain of custody is documented from the US source to the dispensing site. India has a functioning named-patient pathway used routinely across oncology, MS, and rare-disease categories.
How the pathway works, step by step
- Consultation with your treating neurologist. Confirmation of MS subtype, MRI review, prior disease-modifying therapy (DMT) history, and clinical rationale for subcutaneous anti-CD20 therapy versus an infusion-based alternative.
- Pre-treatment screening. Hepatitis B panel (HBsAg and anti-HBc total), baseline serum immunoglobulins (IgG, IgA, IgM), vaccination review with update of live vaccines before depletion, and an active-infection screen.
- CDSCO named-patient application. Your physician or the hospital pharmacy files the application with clinical rationale, patient reference, product details, and a chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Kesimpta from authorised distribution under DSCSA.
- Cold-chain shipment. Kesimpta ships under validated 2-8 degrees C cold chain with continuous temperature logging and chain-of-custody documentation.
- Arrival and first dose. The dispensing hospital pharmacy or licensed clinic releases the loading-dose pens; the first injection is typically observed at the prescribing facility, with subsequent monthly doses self-administered at home.
- Ongoing refill cycle. Reserve Meds maintains the monthly refill rhythm coordinated with your physician visits and immunoglobulin checks.
Where Kesimpta is administered and refilled in India
MS-experienced neurology programmes that have run named-patient anti-CD20 cases include Apollo (Chennai, Hyderabad, Delhi), Tata Memorial associated neurology referrals (Mumbai), AIIMS (New Delhi), Christian Medical College (CMC) Vellore, Max Healthcare (Delhi NCR, Saket and Patparganj), Kokilaben Dhirubhai Ambani Hospital (Mumbai), Medanta The Medicity (Gurgaon), Fortis Memorial Research Institute (Gurgaon, Mulund, Anandapur), and Manipal Hospitals (Bengaluru, Jaipur, Pune). For Kesimpta specifically, because dosing is monthly subcutaneous, the prescribing centre typically observes the first injection and trains the patient and a family caregiver; subsequent monthly doses are self-administered at home with refrigerated supply maintained by the patient. Your neurologist confirms suitability and the local cold-chain handoff.
What documentation your physician needs to provide
- Clinical rationale letter confirming relapsing MS subtype (RRMS, CIS, or active SPMS) and Kesimpta as the indicated therapy
- Verification of Indian medical registration (NMC or state medical council)
- MRI report supporting the diagnosis
- Hepatitis B screening results (HBsAg, anti-HBc) and vaccination history
- Baseline immunoglobulin levels (IgG, IgA, IgM)
- Identification of the prescribing facility and cold-chain handoff plan
- Planned dosing calendar (20 mg SC Weeks 0, 1, 2 loading; 20 mg SC monthly maintenance thereafter)
- Monitoring plan (immunoglobulins, infection surveillance, neurological re-evaluation cadence)
Reserve Meds provides a physician documentation kit bundling templates CDSCO reviewers expect for anti-CD20 MS named-patient imports.
Real cost picture
US WAC reference for Kesimpta is approximately USD 7,400 per 20 mg prefilled pen, with an indicative annual gross WAC range of roughly USD 88,000 to 95,000 depending on loading versus maintenance year (Novartis Investor Relations specialty-portfolio disclosures; US specialty-pharmacy WAC reporting via Drugs.com and GoodRx). US cash-pay specialty-pharmacy networks transact at lower negotiated rates, generally in the range of USD 5,800 to 7,000 per pen for cash-pay export. The loading period (Weeks 0, 1, 2) requires three pens within the first month, raising the first-month cost relative to maintenance months. Cold-chain international logistics, CDSCO documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent itemised quote at the start of intake; these figures are indicative drug-only reference pricing, not the delivered total.
Indicative timing for first dose after cohort intake opens is 7 to 14 days from the moment a complete CDSCO application is submitted. Monthly refills, once the pathway is established and the patient is self-injecting at home, are generally faster, with cold-chain shipments timed to arrive within the four-week interval.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
What to monitor on Kesimpta
Kesimpta sits in the anti-CD20 class with Ocrevus (ocrelizumab), Briumvi (ublituximab), and rituximab (used off-label for MS), but differs in route and frequency: monthly subcutaneous self-injection rather than intravenous infusion. Four safety signals stand out for the Indian patient and the treating neurology team beyond the hepatitis B screening already noted: progressive multifocal leukoencephalopathy as a class consideration, persistent hypogammaglobulinaemia, injection-related reactions (systemic and local), and serious infections. Each is described below with the monitoring cadence and the prescribing-information citation.
Progressive multifocal leukoencephalopathy (PML) and JC virus. Anti-CD20 therapies including ofatumumab carry a class risk for PML, a rare and serious brain infection caused by reactivation of the JC virus in immunosuppressed patients. No PML cases have been reported with ofatumumab in the MS development programme to date, but the Kesimpta label retains PML language as a class effect of anti-CD20 therapies given post-marketing cases reported with other agents in the class (Kesimpta Prescribing Information, section 5.4). Baseline JC virus antibody serology is not mandated by the FDA label before initiation but is often obtained for risk stratification, particularly when sequencing onto Kesimpta from natalizumab (Tysabri). Any new neurological symptom during treatment, including symptoms that do not fit the patient's prior MS relapse pattern, warrants urgent neurology re-evaluation with MRI. Reference: Kesimpta (ofatumumab) Prescribing Information, Novartis, section 5.4.
Hypogammaglobulinaemia and immunoglobulin monitoring. Anti-CD20 monoclonal antibodies deplete B-lymphocytes and, with repeated dosing, reduce circulating immunoglobulin levels over time. The Kesimpta label calls for measurement of quantitative serum immunoglobulins before initiation of Kesimpta, periodically during treatment, and after discontinuation until B-cell repletion (Kesimpta Prescribing Information, section 5.5). MS-experienced Indian centres typically check IgG, IgA, and IgM at baseline and every six months once the patient is established on maintenance. Persistent hypogammaglobulinaemia, in particular IgG below 4 g/L, increases the risk of serious bacterial infection; immunoglobulin replacement (IVIG) may be considered in consultation with immunology if levels remain low and infections recur. References: Kesimpta Prescribing Information, section 5.5; Hauser SL et al., Ofatumumab versus teriflunomide in multiple sclerosis (ASCLEPIOS I and II), N Engl J Med 2020;383(6):546-557.
Injection-related reactions. Unlike infusion-based anti-CD20 therapies, Kesimpta is administered as a subcutaneous self-injection using a prefilled Sensoready pen, so reactions are classified as injection-related rather than infusion-related (Kesimpta Prescribing Information, section 5.2). Two distinct patterns are described in the prescribing information: systemic injection-related reactions (fever, headache, myalgia, chills, fatigue) within 24 hours of injection, which were most common after the first dose and decreased markedly with subsequent doses; and local injection-site reactions (erythema, pain, swelling, pruritus). The first injection is given under healthcare supervision at the Indian prescribing facility; subsequent monthly doses are self-administered at home once patient training is complete. No routine premedication is required, but paracetamol may be considered for symptom management of systemic reactions. Severe reactions, including anaphylaxis, require permanent discontinuation. Reference: Kesimpta Prescribing Information, section 5.2; ASCLEPIOS I and II, N Engl J Med 2020;383(6):546-557.
Serious infections and hepatitis B reactivation. Upper respiratory tract infections were the most common adverse event in the ASCLEPIOS I and II trials (Hauser SL et al., N Engl J Med 2020;383(6):546-557). The Kesimpta label warns of serious bacterial, fungal, and new or reactivated viral infections, including hepatitis B virus reactivation, which can be fatal (Kesimpta Prescribing Information, section 5.6). Given the higher background prevalence of chronic hepatitis B and tuberculosis in parts of India, pre-treatment screening for hepatitis B (HBsAg, anti-HBc total) is mandatory, and a low threshold for tuberculosis screening (Mantoux, IGRA, or chest imaging where clinically indicated) is prudent. Patients with chronic hepatitis B require hepatology co-management and antiviral prophylaxis. Patients with resolved hepatitis B need a frank discussion of reactivation risk and a monitoring plan. Active infection at the time of a scheduled monthly dose warrants delaying that dose until the infection has resolved. Reference: Kesimpta Prescribing Information, section 5.6.
Frequently asked
Is this legal in India? Yes, when executed through the CDSCO named-patient / personal-import framework with appropriate documentation and a licensed prescribing physician. See our trust and compliance page.
Is Kesimpta truly self-administered at home? Yes. After the first observed injection and patient training, subsequent monthly doses are self-administered using the Sensoready prefilled pen. Your neurologist confirms patient suitability and trains the patient and a family caregiver before discharge.
How does Kesimpta compare with Ocrevus, Briumvi, or rituximab? All four are anti-CD20 therapies. Kesimpta is monthly subcutaneous self-injection; Ocrevus is six-monthly IV; Briumvi is IV with shorter infusion times; rituximab is IV and used off-label for MS but is the most established globally. Your neurologist selects based on disease subtype, logistics, and patient preference.
Why hepatitis B screening? Anti-CD20 therapy can reactivate latent hepatitis B, so pre-treatment screening is mandatory under FDA labeling and standard MS practice.
Can Kesimpta be stored at home? Yes. Kesimpta pens are stored refrigerated at 2 to 8 degrees C in the original carton to protect from light. Patients can leave a pen at room temperature (up to 25 degrees C) for up to seven days if needed. Do not freeze. Reference: Kesimpta Prescribing Information, storage and handling.
Will private insurance cover this? Cash-pay is the default. Some Indian private insurers consider named-patient imports case by case; we supply documentation but do not process claims directly.
Recent regulatory and access news for Kesimpta in India
The CDSCO Notifications feed at cdsco.gov.in/Notifications has not posted a Kesimpta-specific notification over the last 12 months as of 2026-06-04. The Drugs Controller General of India has not added Kesimpta to the Approved New Drugs list at cdsco.gov.in Approved-New-Drugs. The National Pharmaceutical Pricing Authority database at nppaindia.nic.in and the Pharmacovigilance Programme of India at ipc.gov.in have not registered Kesimpta-specific signals. Novartis continues commercial rollout of ofatumumab for relapsing multiple sclerosis; the Multiple Sclerosis Society of India and regional MS societies continue to recognise anti-CD20 monoclonal antibodies as a first-line disease-modifying option. We update this section on each case file at intake; the snapshot date governs.
Reserve Meds role
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and CDSCO review.
- Logistics. Validated cold-chain shipment to your prescribing facility, with quarterly or six-monthly refill rhythm coordinated with your neurology visits.
- Concierge case lead. A named point of contact coordinating each monthly cycle and surfacing refill, dosing, and storage questions.
What we do not do: we are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US to overseas). Composite case examples. Not medical advice.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-06-04.